secwatch.observer — SEC 8-K summary
======================================

Issuer:     MARAVAI LIFESCIENCES HOLDINGS, INC. (MRVI)
CIK:        0001823239
Form:       8-K
Filed at:   2026-08-06T20:05:37+00:00
Accession:  0001823239-26-000056
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Maravai Q2 revenue up 8.5% to $51.4M; raises FY2026 Adj EBITDA guidance to $33-35M
--------------------------------------------------------------------------------

- Q2 revenue $51.4M (+8.5% YoY); net loss narrowed to $(21.6)M from $(69.8)M; Adj EBITDA $8.7M vs $(10.4)M loss.
- TriLink revenue $34.7M (+11.5% YoY) driven by Discovery mRNA and GMP consumables; Cygnus $16.8M (+2.8%).
- Full year 2026 Adj EBITDA guidance raised to $33M-$35M; revenue guidance reiterated at $205M-$215M.
- Opened GMP enzyme manufacturing facility; ModTail product line has 125+ active customers including leading biopharma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1823239/000182323926000056/0001823239-26-000056-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1823239/000182323926000056/mrvi-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001823239-26-000056

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer